Study of SYS6020 in BCMA-positive Multiple Myeloma - Trial NCT06359509
Access comprehensive clinical trial information for NCT06359509 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wuhan Union Hospital, China
Timeline & Enrollment
Phase 1
Apr 01, 2024
May 01, 2032
Primary Outcome
Incidence of adverse events (AEs),Dose limiting toxicities (DLTs)
Summary
This is a multi-center, phase I trial that studies the efficacy and recommended dose of BCMA
 CART cells in treating patients with BCMA-positive multiple myeloma (MM) that have not
 respond or relapsed after chemotherapy. B-cell maturation antigen (BCMA), a cell surface
 protein expressed on malignant plasma cell, has emerged as a very selective antigen to be
 targeted in novel immunotherapy for MM.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06359509
Non-Device Trial